CA9 and nonpapillary renal cell carcinoma: One of the first clinical proof of immuno-PET interest has been reported by Divgi et al. (58) with a chimeric mAb (cG250, girentuximab) directed toward the carbonic anhydrase IX (CAIX) cell-surface antigen particularly overexpressed in clear cell renal cell carcinoma (ccRCC).